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Abstract 
 
We developed prototype chemistry for nucleic acid hybridization on our bead-based 
diagnostics platform and we established an automatable bead handling protocol capable 
of 50 part-per-billion (ppb) sensitivity.  We are working towards a platform capable of 
parallel, rapid (10 minute), raw sample testing for orthogonal (in this case nucleic acid 
and immunoassays) identification of biological (and other) threats in a single sensor 
microsystem. In this LDRD we developed the nucleic acid chemistry required for nucleic 
acid hybridization. Our goal is to place a non-cell associated RNA virus (Bovine Viral 
Diarrhea, BVD) on the beads for raw sample testing.  This key pre-requisite to showing 
orthogonality (nucleic acid measurements can be performed in parallel with 
immunoassay measurements). Orthogonal detection dramatically reduces false positives.  
We chose BVD because our collaborators (UC-Davis) can supply samples from 
persistently infected animals; and because proof-of-concept field testing can be 
performed with modification of the current technology platform at the UC Davis research 
station. Since BVD is a cattle-prone disease this research dovetails with earlier 
immunoassay work on Botulinum toxin simulant testing in raw milk samples. 
Demonstration of BVD RNA detection expands the repertoire of biological 
macromolecules that can be adapted to our bead-based detection. The resources of this 
late start LDRD were adequate to partially demonstrate the conjugation of the beads to 
the nucleic acids. It was never expected to be adequate for a full live virus test but to 
motivate that additional investment. In addition, we were able to reduce the LOD (Limit 
of Detection) for the botulinum toxin stimulant to 50 ppb from the earlier LOD of 1 ppm.  
A low LOD combined with orthogonal detection provides both low false negatives and 
low false positives.  The logical follow-on steps to this LDRD research are to perform 
live virus identification as well as concurrent nucleic acid and immunoassay detection. 
4 
 
 
ACKNOWLEDGMENTS 
 
Sandia is a multi-program laboratory operated by Sandia Corporation, a Lockheed Martin 
Company, for the United States Department of Energy’s National Nuclear Security 
Administration under contract DE-AC04-94AL85000.  We thank the LDRD office and 
the Nano to Microsystems investment area at Sandia for funding this research.  We also 
thank A. Kommandoor and K. Ortiz for their assistance and guidance.
5 
 
 
 
CONTENTS 
1.  Introduction.................................................................................................................... 7 
2. BVD Assay ..................................................................................................................... 9 
3. Increased Technology Platform Sensitivity (lowering LOD)....................................... 11 
4. Conclusions and Next Steps.......................................................................................... 13 
5. References..................................................................................................................... 14 
 
6 
 
 
FIGURES 
Figure 1.  Two-Stage BVD Hybridization Assay.  Top (a) shows whole illustration of the 
a two-stage hybridization assay that we are developing. This first phase of the 
development allows us to perform two critical components for nucleic acid development. 
The first is the establishment of the assay using primers on grown virus (performed at 
UCD DVM in Tulare, CA) (c – lower right) and the second was the conjugation of 
primer onto a magnetic bead similar to those used on the basic bead platform (b – lower 
left)...................................................................................................................................... 9 
Figure 2.  Demonstration of Biotinated Oligo binding to streptavidin coated magnetic 
beads (sub-assay of Figure 1(b))....................................................................................... 10 
Figure 3. Sensitivity of detection technology platform demonstrated to 100 ppb............ 12 
 
7 
1.  INTRODUCTION  
 
In the current threat climate pertaining to chemical, biological or nuclear weapons of 
mass destruction (CBN WMD) there is a need for a rugged, unobtrusive, mass deployable 
detector/sensor that can rapidly identify a wide variety of potential CBN agents (target 
molecules – toxins, proteins, cells, viruses or actinides) at low concentrations in raw 
samples.  Such a sensor could, for instance, be used by soldiers on a battlefield to 
determine if they are under chemical or biological attack, or as part of an automated early 
warning alarm in a major city mass transit system, or as a tool for inspectors searching 
for evidence.    
 
Due to the rapid propagation of disease organisms within the human body and their high 
lethality, early detection and classification is essential. Much of this is articulated in the 
February 2001 report on “Biological Detection System Technologies – Technology and 
Industrial Base Study,” prepared by TRW 1 and “Sensor Systems for Biological Agent 
Attacks: Protecting Buildings and Military Bases”2 These are detailed studies focusing on 
early Bio-warfare agent (BW) detection and identification technologies for the US 
military. 
 
A portable, modular diagnostic system for CBN detection must rapidly and accurately 
identify the onset of an attack by sensing one or more of the following diagnostic markers 
associated with the agents: 
 
 Agent itself/toxin, toxic industrial chemical, Antigen, Antibody, Cytokines/Chemokines,  
 Radionuclide (i.e. Pu, U, etc.) 
 Deoxyribonucleic Acid (DNA) or Ribonucleic Acid (RNA) 
 
Diagnostic speed and accuracy are foremost requirements in battlefield settings subject to 
these WMD warfare attacks.  Assay accuracy is described in terms of sensitivity and 
specificity to a specific diagnostic signature. Since false negatives and false positives are 
likely, particularly during presymptomatic stages of infection or exposure, and would 
directly affect the readiness and morale of a unit, it is imperative that a portable 
diagnostic system contain primary and secondary assays for agents of interest. It is 
envisioned that these assays detect and identify different features of a given biomarker, 
e.g., nucleic acid and peptide coat, to ensure orthogonality of the two assays. 
 
 
The “Bead-based Multiplexed, Orthogonal BW/ID (BioWarfare/Infectious Disease) 
Detection Microsystem” was an earlier LDRD to perform proof-of-principle experiments 
for the concept of a raw sample, rapid assay detection scheme. This LDRD was 
successful: we have a crude prototype3, a detailed model4, and excellent results with a 
Botulinum Toxin surrogate (ovalbumin) in raw milk. We have extended that earlier work 
to include detection of actinides and lanthanides with collaborators from Argonne 
National Laboratory.5  
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The purpose of this LDRD was to expand the target sensitivity of the bead-based assay 
and technology to nucleic acids, thereby allowing orthogonal detection.  The target 
prototype nucleic acid we have chosen is BVD (Bovine Viral Diarrhea).   BVD is an 
RNA virus in the pestivirus (family, Arenavirus), that gives rise to a number of viral 
hemorrhagic fevers. Hemorraghic fevers are the most prevalent diseases on the Category 
A list of the National Institutes of Health and the Center for Disease Control.  RNA 
provides a more rigorous proof of the technology platform than deoxyribonucleic acid 
(DNA) due to the chemical instability of RNA. 
 
In this LDRD we plan to test the viability of performing rapid RNA analysis on raw 
samples in the field using BVD as the target nucleic acid.  This work begins the effort to 
develop nucleic acid hybridization assays on our magnetic beads. We continued our 
collaboration with the UC-Davis veterinary college in Tulare, CA with the Director Jim 
Cullor and Paul Rossitto, DVM (Department of Veterinary Medicine).  Our collaborators 
can supply samples from persistently BVD infected animals and the proof-of-principle 
(POP) testing can be done in the field at Tulare.  
 
Upon completion of the bead-based BVD assay we believe that we will have added 
nucleic acid processing to our technology platform. This means a distinct step towards 
completion of scientific proof-of-principle for a platform capable of accepting many raw 
samples for rapid, concurrent immunoassay and nucleic acid assay detection (orthogonal 
detection – low false positive). The implication is that we will have proven the basic 
science for a detection platform capable of meeting and exceeding the full suite of Joint 
Biological Agent Identification and Diagnostic System (JBAIDS)6 long-term mission 
needs. 
 
The second focus of this LDRD was to reduce the LOD (limit of detection) achievable 
with our assay technology – specifically the two-wavelength optical detection system and 
mixing and bead/sample handling techniques used by our system platform – using the 
prototype substitute botulinum toxin chemistry (Ova assay, Ovalbumin/antiOvalbumin 
immunoassay).   Our summer student, Cara Farrell, was able to reduce the LOD from 1 
ppm (part-per-million) to from 50-100 ppb (parts-per-billion).  This reduction in LOD 
involved additional fluid handling automation – automated mixing.  The goal is to 
achieve 1 ppb LOD with a high level of system automation for assay repeatability.  By 
lowering the LOD the likelihood of false negative errors is reduced, and by incorporating 
an orthogonal assay (nucleic acid assay) the likelihood of false positive errors is reduced.  
In this LDRD we demonstrated both a partial ability to perform nucleic acid assays 
(BVD), and a high level of sensitivity, low LOD (Ova assay) with our bead-based 
technology platform. 
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2. BVD ASSAY  
 
Cost and biohazard issues set the stage for the scope of this work. For the budget 
available it was not feasible to either set up a local laboratory for processing live BVD 
virus nor to ship our system to Tulare CA to do performance testing. What was proposed 
was to simulate the assay in a two step process. The process is shown graphically in Fig. 
1. In Fig.1(a) (top) the complete assay is shown.  In Fig 1(b) (lower left) and 1(c) (lower 
right) the complete assay is split into two sub-assays.  Sub-assay 1(b) was to be 
performed at Sandia National Laboratories and sub-assay 1(c) at UC Davis. 
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Figure 1.  Two-Stage BVD Hybridization Assay.  Top (a) shows whole illustration of the a 
two-stage hybridization assay that we are developing. This first phase of the development 
allows us to perform two critical components for nucleic acid development. The first is the 
establishment of the assay using primers on grown virus (performed at UCD DVM in 
Tulare, CA) (c – lower right) and the second was the conjugation of primer onto a magnetic 
bead similar to those used on the basic bead platform (b – lower left). 
 
The assay reagents were purchased from Operon Biotechnologies Inc and consist of the 
Oligo (oligo-nucleid) (BioTEG)TAGCCATGCCTTAGTAGGAC(AmC7-Q+Alexa660)  
(complimentary oligo to BVD) attached to biotin at one end and a dye marker Alexa-
fluor600 at the other end.  The biotin end of the molecule binds to our internally labeled 
streptavidin coated magnetic beads. This oligo, with dye attached, was simply used to 
validate the fact that indeed the oligo was attached to the bead.  From the success of this 
attachment we conclude that success is highly probable for the attachment of an identical 
oligo, capable of binding the BVD RNA, without the dye molecule attached.  The 
biotinated oligo specific to BVD did not arrive at Sandia National Laboratories in time 
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for us to perform the assay.  However we were able to use a substitute biotinated Olig 
[(5’biotin)5’-
AATACCTTTCTTGGGGTAATACTCATCGCGAATATCCTTAAGAGGGCGTTCAG
C-3’(Atto-655 NHS ester dye)] to demonstrate oligo attachment to our beads.  See Figure 
2. 
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Figure 2.  Demonstration of Biotinated Oligo binding to streptavidin coated 
magnetic beads (sub-assay of Figure 1(b)). 
 
Significantly higher signal was obtained with the atto655-oligo combination over both 
beads alone and atto655 (no oligo) indicating that the oligo did bind to the beads.  The 
fact that there was significant signal with the beads plus atto655 case indicates that non-
specific binding is an issue.  Instead: This non specific binding is probably due to 
unbound atto655 dye not being separated for oligo bound atto-655 dye using a precise 
size exclusion column, such as utilized in HPLC, prior to mixing with the beads. 
 
We did not accomplish the full two-part assay shown in Figure 1a.  The part of the assay 
shown in Figure 1c was not accomplished because the reagents did not arrive at UC 
Davis in time for the live BVD virus part of the assay to be completed.  The part of the 
assay shown in Fig. 1b was accomplished, but not with the exact oligo, rather with an 
substitute oligo (data shown in Fig. 2).  Based on previous experience we estimate that 
approximately 1 month of work would be required to finish part b of the assay (bead 
functionalization), with a similar amount of work required to finish part c of the assay 
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(virus labeling).  At that point we would be ready to ship our detection system to Tulare 
CA and conduct the full Figure 1 assay (a two week test).   
 
3. INCREASED TECHNOLOGY PLATFORM SENSITIVITY 
(LOWERING LOD) 
 
Several steps were taken to reduce the LOD from ppm towards ppb during this LDRD.  
The ova-assay was used as the well understood workhorse chemistry on which to try 
various different technology changes.  The signal/noise ratio (S/N) for the ova-assay was 
utilized as the figure of merit to determine the effectiveness of the different technology 
changes investigated.  In our previous experience with the ova-assay, we achieved S/N of 
approximately 2:1 at 1 ppm.  This was the minimum S/N that allowed identification 
without too high a false positive or too high a false negative.  In the research summarized 
here we consistently achieved 2:1 S/N with a concentration of 50-100 ppb.  Therefore 50-
100 ppb is our new lower LOD (see Fig. 3).   
 
The detection technology system that we utilized consists of two subsystems: 1) an 
optical detector, and 2) a fluid handling protocol.  The optical detector consists of two 
excitation sources, a microscope, a sensitive CCD array, internal software, and two sets 
of filters that allow us to conduct two-wavelength detection of first; bead presence at a 
pixel and second; captured fluorescent tag at the same pixel location.  This concurrent 
two-wavelength signal allows a higher degree of certainty that a true positive 
identification has occurred, indicating that the sandwich assay reaction on which 
detection is based has occurred.  The variations in the optical part of the detection system 
that were investigated included; signal integration time, optical interrogation illumination 
intensity, and software background subtraction.    The software background subtraction 
allows us to determine a positive signal identification for a S/N ~ 2.  Improvements to the 
background subtraction software should allow us to extend our positive signal 
identification S/N to < 2, and allow us to extend our LOD < 50 ppb.  However, we have 
not done enough repeat data points at this condition to rigorously make this claim.  
 
The fluid handling technology was based on pipetting samples and reagents (beads and 
dye labeled antibodies required for sandwich assay – see Fig. 1) together into small test 
tube volumes (~100’s l typical), and then mixing the sample with the reagents using a 
commercial mixing technology or by pipette mixing, followed by pelleting the beads, 
washing away the unwanted unbound sample constituents, and pipetting a drop of bead 
sample onto a microscope slide for optical interrogation.  The key parameters that were 
investigated as part of this research were mixing process (two commercial mixers and 
hand hand pipette mixing or finger-flick mixing), mixing time (2 to 30 minutes), pellet 
clean-up techniques (pipette tip diameter, centrifuge rpm, magnetic hold-down), buffer 
concentration, and number of beads.  The best combination of parameters that resulted in 
the 100 ppb or better (50 ppb) consisted of : 
 
1) Rotating mixer (model m90615, LabquakeTM Rotisserie ) at 8 rpm rotation rate. 
2) 10 minute mixing 
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3) Small pipette tip cleanup up with centrifuge set at 2000 rpm for 2 minutes for 
pelleting and magnetic assist in pellet immobilization 
4) 1X buffer concentration (lower ion concentration) 
5) 106 beads (or greater). 
 
To reduce the LOD even further (our goal is to achieve 1 ppb) we propose to investigate:  
 
1) increasing the number of beads further 
2) < 1X buffer concentration (lower ionic strength at pH 7). 
3) Bead diameter. 
4) Optimizing mixing time/method. 
5) Improved pipetting/pelleting. 
6) Full implementation of software improvements for background correction. 
 
All of these factors can be automated and integrated into a single micro-to-meso scale 
system that should result in a consistently lower LOD (remove pipette operator 
varations).  Currently we have consistently achieved 100 ppb, in some cases achieved 50 
ppb and can potentially achieve 1 to 10 ppb with the implementation of these technology 
improvements.   
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Figure 3. Sensitivity of detection technology platform demonstrated to 100 ppb.    
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4. CONCLUSIONS AND NEXT STEPS 
 
In conclusion, during this LDRD progress was made towards reaching our goal of 
developing the ability to conduct fully orthogonal (nucleic and immunoassay), low LOD 
(limit of detection) assays with our suite of technologies.  This ability will allow us to 
rapidly process samples, and identify multiple threat agents with a high level of 
sensitivity (low false negatives) and specificity (low false positives).  Specifically, in this 
research we demonstrated a new low LOD of 50 to 100 ppb with our optical and fluid 
handling technology; and we partially demonstrated a bead-based nucleic (oligo) assay 
using BVD (bovine viral diarrhea) as a target oligo threat of interest by attaching an oligo 
to a bead. 
 
The remaining steps that need to be taken to reach orthogonal high sensitivity detection 
with our technology platform include: 
 
1)  Attach specific anti-BVD oligo to bead. 
2)  Attach anti-BVD to dye marker. 
3) Perform simultaneous sandwich assay using BVD and items (1) and (2) of this list. 
4) Reduce LOD from 50 to 100 ppb to 1 to 10 ppb using the techniques outlined in 
section 3. 
5)  Perform items (3) and (4) of this list simultaneously in the same sample. 
6)  Automate the detection process and technologies. 
7) Explore possible collaborations that allow application of this detection technology in 
the dairy industry. 
8)  Explore other national security application for this technology platform in the CBN 
area. 
 
Completion of these steps would result the application of this research to important 
national security concerns, thereby fulfilling the mission of the LDRD process and 
Sandia National Laboratories.
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